With the Raypilot System, we can see exactly where we are delivering the radiation. Being able to deliver the dose in the right place at the right time gives us confidence in the treatment. Above all, this allows our patients to benefit from a safe, modern and efficient treatment method with a reduced risk of side effects.

A technology that reduces side‑effects and, in combination with the right radiation, constitutes a fully adequate treatment - why isn’t it used? It was incomprehensible to me, and I had to find out more.

I needed to convince myself that this actually works, so I played the devil’s advocate, dug deep into the dossiers and asked the tough questions. And I found answers to all of them. The only negative that emerged was that the catheter can be perceived as a little uncomfortable, but this is a discomfort patients readily accept considering all the other benefits,

When I compiled the available facts, it became very clear that the Raypilot System contributes to substantially reduced side‑effects and that ASBRT in combination with the Raypilot System is the best option for the patient. It all comes down to the precision the system provides.

The more I’ve learned about ASBRT and the Raypilot System, the more important it feels to help increase awareness and adoption. I believe it is almost unethical that these opportunities are not offered to more patients. Moreover, they make healthcare more efficient, so this is not a matter of cost. If anything, it’s the opposite.

There are sufficient studies and facts to be confident this works. Now it needs to reach university hospitals and larger care providers. And I think we can move from talking about reduced side‑effects with the Raypilot System to no side‑effects – when performed correctly this is fully achievable, which is already being demonstrated in practice.

We are pleased with the very positive reception of Augmented SBRT. Now we will continue to work together with clinical researchers and industry partners to raise awareness and increase knowledge about the available treatment opportunities. There is a lot to gain here, primarily regarding the patients' quality of life, but also socio-economic benefits due to the efficiency these modern treatments offer healthcare providers.

The goal is treatment in five or fewer sessions with zero side effects. That’s entirely possible and already being done today.

The advantage of being able to monitor the position of the prostate in real time with millimetre accuracy during radiotherapy is that margins to surrounding healthy tissue can be significantly reduced. This means side effects to, for example, the rectum, bladder and the nerves and blood vessels important for erectile function can be minimised. But the most important benefit is that you ensure the tumour receives the full intended dose, reducing the risk of underdosing and recurrence.

The goal of the Precision Study is to ensure that treatment with three radiation doses does not lead to greater side effects than those observed in the Pace-B study. I am confident that we can demonstrate effective cancer treatment with less side effects.

Our customers are interested in developing and improving healthcare, always with patient quality of life in focus. At the same time, healthcare providers across the Western world are striving to reduce treatment times and enhance both quality and efficiency. This study could contribute to such progress, benefiting all stakeholders—healthcare providers reduce costs while improving care, and patients gain a better quality of life.

It is highly reasonable to assume that if the study had been conducted using the technology available today, the radiation-treated patients would have experienced even fewer side effects.

It’s high time to start focusing on the quality of life for prostate cancer patients after treatment. Both radiation and surgery are effective in curing early-stage prostate cancer. But the differences in terms of side effects are significant and must be taken seriously. That is why this study is so essential. The results are highly relevant for healthcare providers and patient organizations, and it’s important that this knowledge also reaches patients.

With the publication of this comparative study, we now have evidence that SBRT treatment provides results equal to conventional treatment. It's likely that SBRT will, in the foreseeable future, not only become approved but also recommended as standard treatment for localized prostate cancer in several countries, including Switzerland, Italy, and the United Kingdom.

A higher radiation dose delivered with great accuracy gives patients effective treatment with very little risk of side effects. This significantly impacts patients' quality of life after treatment. Additionally, treatment becomes more convenient, completed in just five days instead of potentially seven weeks or more. For healthcare providers, the reduced number of treatments represents significant efficiency gains and an opportunity to shorten the long waiting lists in cancer care that in many places still persist since the pandemic.